RenovoRx, Inc. (RNXT)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
March 2026
RenovoRx, Inc. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing, which is a current report companies use to announce major events to shareholders. This specific filing includes the full-year 2025 financial results and a detailed business update. Think of it as a "state of the union" for investors, showing where th
SEC filings
All filings →Insider trades
All insider trades →RenovoRx, Inc. has no reported insider trades in the last 90 days.